Global IGY Polyclonal Antibodies Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global IGY Polyclonal Antibodies Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Immunoglobulin Y (abbreviated as IgY) is a type of immunoglobulin which is the major antibody in bird, reptile, and lungfish blood. It is also found in high concentrations in chicken egg yolk. As with the other immunoglobulins, IgY is a class of proteins which are formed by the immune system in reaction to certain foreign substances, and specifically recognize them.
IgY antibodies have a different structure from IgG, particularly in the Fc and hinge regions. The affinity maturation process of IgY is also different from IgG. These biological features underlie IgY's competitive advantages over IgG. Shown in the four panels are several comparisons between IgY and IgG.
IgY is a hen egg polyclonal antibody. Hen eggs contain more than 450 separate antibodies and when consumed, are not rejected by the human immune system.
The scientific community has long known that IgY has the proven ability to modulate immune systems. The G.I. tract is the typical entry point for foreign pathogens. By removing pathogens IgY can alleviate stress on the overall system thereby optimizing the body’s natural defense systems. When consumed orally or topically, IgY can identify and attack foreign pathogens that enter via the gut. Antibodies work on both viral and bacterial infections possibly reducing the need for antibiotics.
IgY antibodies have been studied extensively by many government, university and private industry research groups over the years, all concluding the efficacy of IgY in improving overall health. IgY has been used safely in nutraceuticals and vitamins for many years.
IGY Polyclonal Antibodies report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global IGY Polyclonal Antibodies market is projected to reach US$ 15 million in 2034, increasing from US$ 7 million in 2022, with the CAGR of 11.1% during the period of 2024 to 2034. Demand from Academic Research and Commercial are the major drivers for the industry.
The classification of IGY Polyclonal Antibodies includes Primary Antibody and Secondary Antibody. The proportion of Primary Antibody is about 70%, and the proportion of Secondary Antibody is about 30%.
IGY Polyclonal Antibodies are application in Academic Research and Commercial. The most of IGY Polyclonal Antibodies is used in Commercial, and the market share of that is about 60%.
North America is the largest consumption place, with a consumption market share nearly 37%, Europe is the second largest consumption place with the consumption market share of 30%.
Market competition is not intense. Merck, IGY Life Sciences, Abcam, Genway Biotech, Good Biotech etc. are the leaders of the industry with the market share are about 66%.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global IGY Polyclonal Antibodies market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
Merck
IGY Life Sciences
Abcam
Genway Biotech
Good Biotech
Gallus Immunotech
Creative Diagnostics
Agrisera
Innovagen AB
Capra Science
YO Proteins
GeneTex
Segment by Type
Primary Antibody
Secondary Antibody
Academic Research
Commercial
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the IGY Polyclonal Antibodies market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, IGY Polyclonal Antibodies introduction, etc. IGY Polyclonal Antibodies Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12QYResearch’s Conclusions of IGY Polyclonal Antibodies market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by QYResearch.
IgY antibodies have a different structure from IgG, particularly in the Fc and hinge regions. The affinity maturation process of IgY is also different from IgG. These biological features underlie IgY's competitive advantages over IgG. Shown in the four panels are several comparisons between IgY and IgG.
IgY is a hen egg polyclonal antibody. Hen eggs contain more than 450 separate antibodies and when consumed, are not rejected by the human immune system.
The scientific community has long known that IgY has the proven ability to modulate immune systems. The G.I. tract is the typical entry point for foreign pathogens. By removing pathogens IgY can alleviate stress on the overall system thereby optimizing the body’s natural defense systems. When consumed orally or topically, IgY can identify and attack foreign pathogens that enter via the gut. Antibodies work on both viral and bacterial infections possibly reducing the need for antibiotics.
IgY antibodies have been studied extensively by many government, university and private industry research groups over the years, all concluding the efficacy of IgY in improving overall health. IgY has been used safely in nutraceuticals and vitamins for many years.
IGY Polyclonal Antibodies report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global IGY Polyclonal Antibodies market is projected to reach US$ 15 million in 2034, increasing from US$ 7 million in 2022, with the CAGR of 11.1% during the period of 2024 to 2034. Demand from Academic Research and Commercial are the major drivers for the industry.
The classification of IGY Polyclonal Antibodies includes Primary Antibody and Secondary Antibody. The proportion of Primary Antibody is about 70%, and the proportion of Secondary Antibody is about 30%.
IGY Polyclonal Antibodies are application in Academic Research and Commercial. The most of IGY Polyclonal Antibodies is used in Commercial, and the market share of that is about 60%.
North America is the largest consumption place, with a consumption market share nearly 37%, Europe is the second largest consumption place with the consumption market share of 30%.
Market competition is not intense. Merck, IGY Life Sciences, Abcam, Genway Biotech, Good Biotech etc. are the leaders of the industry with the market share are about 66%.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global IGY Polyclonal Antibodies market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
By Company
Merck
IGY Life Sciences
Abcam
Genway Biotech
Good Biotech
Gallus Immunotech
Creative Diagnostics
Agrisera
Innovagen AB
Capra Science
YO Proteins
GeneTex
Segment by Type
Primary Antibody
Secondary Antibody
Segment by Application
Academic Research
Commercial
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the IGY Polyclonal Antibodies market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, IGY Polyclonal Antibodies introduction, etc. IGY Polyclonal Antibodies Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12QYResearch’s Conclusions of IGY Polyclonal Antibodies market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices